The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma
GSTP1
DOI:
10.1097/fpc.0b013e32834e3572
Publication Date:
2011-12-01T17:53:57Z
AUTHORS (6)
ABSTRACT
Identification of biomarkers that could predict gemcitabine efficacy and toxicity is a key issue in the development individualized therapy. The aim our study was to evaluate influence pathway polymorphisms on treatment outcome patients with malignant mesothelioma (MM).In total, 107 MM, treated gemcitabine-platinum chemotherapy, were genotyped for 11 deoxycytidine kinase, ribonucleotide reductase M1 (RRM1), cytidine deaminase genes using KASPar assays. Binary logistic regression used selected tumor response occurrence treatment-related toxicity, while their survival estimated by Cox proportional hazards model. A haplotype analysis carried out assess combined effect RRM1 polymorphisms.Deoxycytidine kinase did not MM. In multivariable analysis, 2927A>C polymorphism significantly decreased overall probability [hazard ratio (HR)=2.02; 95% confidence interval (CI)=1.11-3.65; P=0.021]. Two promoter polymorphisms, -524T>C -37C>A, odds nausea/vomiting grade≥2 [odds (OR)=0.25; CI=0.10-0.60; P=0.002 OR=0.26; CI=0.11-0.63; P=0.003, respectively]. TTCCA associated worse (OR=16.67; CI=2.38-100.00; P=0.004) (HR=2.97; CI=1.46-6.06; P=0.003) compared most frequent TTCAA haplotype, TCACA influenced (OR=0.27; CI=0.12-0.60; P=0.001).RRM1 as well haplotypes showed an association toxicity; therefore, they should be validated potential markers prediction clinical
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (48)
CITATIONS (25)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....